Keywords: Abbott Labs, HCV regimen, Interferon-free, Hepatitis C
Abbott Lab's HCV regimen achieves near complete cure rates in mid-stage trial
Article | 16 October 2012
USA-based Abbott Laboratories (NYSE ABT) announced strong initial results from “Aviator," a Phase IIb study of its interferon-free, investigational ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
